Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

被引：145
作者：
Kappel, Ben A. [1 ]
Lehrke, Michael [1 ]
Schutt, Katharina [1 ]
Artati, Anna [2 ]
Adamski, Jerzy [2 ,3 ,4 ]
Lebherz, Corinna [1 ]
Marx, Nikolaus [1 ]
机构：
[1] Rhein Westfal TH Aachen, Univ Hosp Aachen, Dept Internal Med 1, Pauwelsstr 30, D-52074 Aachen, Germany
[2] German Res Ctr Environm Hlth, Helmholtz Zentrum Muchen, Genome Anal Ctr, Inst Expt Genet, Neuherberg, Germany
[3] Tech Univ Munich, Life & Food Sci Ctr Weihenstephan, Inst Expt Genet, Freising Weihenstephan, Germany
[4] German Ctr Diabet Res, Neuherberg, Germany
来源：
CIRCULATION | 2017年 / 136卷 / 10期
关键词：
branched-chain amino acids; cardiovascular disease; empagliflozin; ketone bodies; metabolomics; SGTL2; inhibitors; type 2 diabetes mellitus; OUTCOMES;
D O I：
10.1161/CIRCULATIONAHA.117.029166
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：969 / 972
页数：4
相关论文
共 50 条
[41]   Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial [J].
Jurgens, Mikkel ;
Schou, Morten ;
Hasbak, Philip ;
Kjaer, Andreas ;
Wolsk, Emil ;
Zerahn, Bo ;
Wiberg, Mikkel ;
Brandt-Jacobsen, Niels H. ;
Gaede, Peter ;
Rossing, Peter ;
Faber, Jens ;
Inzucchi, Silvio E. ;
Gustafsson, Finn ;
Kistorp, Caroline .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (15)
[42]   Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension [J].
Ferdinand, Keith C. ;
Izzo, Joseph L. ;
Lee, Jisoo ;
Meng, Leslie ;
George, Jyothis ;
Salsali, Afshin ;
Seman, Leo .
CIRCULATION, 2019, 139 (18) :2098-2109
[43]   Review of empagliflozin monotherapy for previously untreated patients with type 2 diabetes mellitus: Comparison with sitagliptin [J].
Cornell, Susan .
POSTGRADUATE MEDICINE, 2015, 127 (03) :277-281
[44]   Comparison of the effects of empagliflozin and sitagliptin, as add-on to metformin, on serum levels of asprosin and metabolic parameters in patients with type 2 diabetes mellitus [J].
Talebi, Seyed Saman ;
Rezaie, Shabnam ;
Hajmiri, Minoo Sadat ;
Zamanirafe, Maryam ;
Ranjbar, Akram ;
Moridi, Heresh ;
Mirjalili, Mahtabalsadat ;
Mehrpooya, Maryam .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 (11) :9149-9165
[45]   Pilot study in pharmacogenomic management of empagliflozin in type 2 diabetes mellitus patients [J].
Jamalizadeh, Mahdieh ;
Hasanzad, Mandana ;
Sarhangi, Negar ;
Sharifi, Farshad ;
Nasli-Esfahani, Ensieh ;
Larijani, Bagher .
JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2021, 20 (02) :1407-1413
[46]   The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial [J].
Shojaei, Fatemeh ;
Erfanifar, Azam ;
Kalbasi, Saeid ;
Nikpour, Shahriar ;
Gachkar, Latif .
BMC ENDOCRINE DISORDERS, 2025, 25 (01)
[47]   Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus [J].
Triplitt, C. ;
Solis-Herrera, C. ;
Cersosimo, E. ;
Abdul-Ghani, M. ;
Defronzo, Ralph A. .
EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (18) :2819-2833
[48]   Pilot study in pharmacogenomic management of empagliflozin in type 2 diabetes mellitus patients [J].
Mahdieh Jamalizadeh ;
Mandana Hasanzad ;
Negar Sarhangi ;
Farshad Sharifi ;
Ensieh Nasli-Esfahani ;
Bagher Larijani .
Journal of Diabetes & Metabolic Disorders, 2021, 20 :1407-1413
[49]   Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus [J].
Salukhov, Vladimir V. ;
Demidova, Tatiana Y. .
DIABETES MELLITUS, 2016, 19 (06) :494-510
[50]   Lipoprotein(a) concentrations in patients with type 2 diabetes mellitus without cardiovascular disease:: relationship to metabolic parameters and diabetic complications [J].
Tarkun, I ;
Çetinarslan, B ;
Cantürk, Z .
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2002, 12 (03) :127-131
12345